Skip to main content

Advertisement

Table 2 Identified metabolites associated with achieving sustained drug-free remission in the three strategy arms

From: Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology

Tocilizumab plus methotrexate SMD p value Tocilizumab SMD p value Methotrexate SMD p value
Histamine − 1.75 0.002 PGE2▲ 0.93 0.019 L-Lysine▲ 0.95 0.032
9,12,13-TriHOME▲ 0.52 0.002 L-Pipecolic acid▲ 0.42 0.026 L-Proline▲ 0.98 0.040
Spha c18:0 − 1.34 0.007 8,9-DiHETrE▲ 0.81 0.026 3-Methylhistidine − 1.05 0.06
9,10,13-TriHOME▲ 1.05 0.010 5,6-DiHETrE▲ 0.79 0.034 Anserine▲ 0.73 0.06
LPA c20:3 − 1.29 0.012 8-iso-PGE2▲ 0.89 0.034 19,20-DiHDPA − 1.03 0.06
Sph c18:1 − 0.83 0.012 20-carboxy-LTB4▲ 0.50 0.035 5-Hydroxy-L-tryptophan − 0.40 0.08
LPA c18:1 − 0.93 0.033 Cystathionine − 0.96 0.052 L-Arginine▲ 0.98 0.08
L-Methionine sulfoxide▲ 1.01 0.033 Norepinephrine − 0.39 0.052 LPA c18:3 (w3/w6)▲ 0.80 0.08
8,9-DiHETrE − 0.94 0.042 3-Methylhistidine − 0.61 0.07 12,13-DiHODE − 0.60 0.10
LPA c16:0 − 0.81 0.052 TXB2▲ 0.82 0.08 14,15-DiHETE − 0.96 0.10
NO2-OA − 0.98 0.052 8-iso-PGA2▲ 0.58 0.08 cLPA c16:0▲ 0.71 0.10
L-Kynurenine − 1.03 0.06 aLPA c16:1 − 0.24 0.08 PAF c16:0▲ 0.87 0.10
LPA c22:4 − 1.03 0.06 Homocysteine − 0.78 0.09    
LPA c20:4 − 0.97 0.06       
Methyldopa − 0.88 0.08       
PGD2▲ 0.02 0.08       
LPA c16:1 − 0.84 0.08       
Hydroxylysine▲ 0.66 0.10       
PGF3a▲ 0.07 0.10       
12,13-DiHODE▲ 0.85 0.10       
  1. ▲On average, higher concentration in the sDFR group vs controls; on average, lower concentration in the sDFR group vs controls. sDFR sustained drug-free remission, SDM standardized mean difference